Amphotericin B deoxycholate

First approved in 1958

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C47H73NO17.C24H39O4.Na
Molecular Weight	1338.6328
Optical Activity	UNSPECIFIED
Defined Stereocenters	29 / 29
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Amphotericin B deoxycholate

Structure Search

SMILES

[Na+].C[C@H](CCC([O-])=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.C[C@H]5O[C@@H](O[C@@H]6C[C@@H]7O[C@@](O)(C[C@H](O)[C@H]7C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\6)[C@@H](O)[C@@H](N)[C@@H]5O

InChI

InChIKey=NFHDUMMQBQTVTR-OXEBIIQQSA-M

InChI=1S/C47H73NO17.C24H40O4.Na/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56;1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3;/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60);14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;;+1/p-1/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+;;/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+;14-,15-,16-,17+,18-,19+,20+,21+,23+,24-;/m01./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H39O4
Molecular Weight	391.5641
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C47H73NO17
Molecular Weight	924.079
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	19 / 19
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869574http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf
Curator's Comment: Description was created based on several sources, including: http://www.drugs.com/monograph/amphotericin-b.html https://en.wikipedia.org/wiki/Amphotericin_B#cite_note-45 http://www.drugbank.ca/drugs/DB00681

Amphotericin B used to treat progressive, potentially life-threatening fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Also, Amphotericin B is often used in otherwise-untreatable protozoan infections such as visceral leishmaniasis and primary amoebic meningoencephalitis. As with other polyene antifungals, amphotericin B binds with ergosterol, a component of fungal cell membranes, forming a transmembrane channel that leads to monovalent ion (K+, Na+, H+ and Cl−) leakage, which is the primary effect leading to fungal cell death. When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents, Corticosteroids and Corticotropin (ACTH); Digitalis glycosides; Flucytosine; Imidazoles (e.g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.); Zidovudine; Skeletal muscle relaxants (tubocurarine); Rifabutin; Leukocyte transfusions. The adverse reactions most commonly observed are: fever; malaise; weight loss; hypotension; tachypnea; anorexia; nausea; vomiting; diarrhea; dyspepsia; cramping epigastric pain; normochromic, normocytic anemia; pain at the injection site with or without phlebitis or thrombophlebitis; generalized pain, including muscle and joint pains; headache; decreased renal function and renal function abnormalities.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Ergosterol 7 Target ID: CHEMBL2364028 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19689243	Binding Agent 1076
cell wall organization 4 Target ID: GO:0071555 Sources: https://www.aceabiotech.com/corifungin/ \| https://www.ncbi.nlm.nih.gov/pubmed/24366747	Interacts 323

Conditions

Condition	Modality	Highest Phase	Product
Mycoses 12 Sources: https://www.aceabiotech.com/corifungin/ https://www.aceabiotech.com/clinical-development-of-corifungin/	Curative	Preclinical	Unknown Approved Use Unknown
Naeglerias 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869574 https://www.aceabiotech.com/corifungin/	Curative	Preclinical	Unknown Approved Use Unknown
Cryptococcosis 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Blastomycosis 7 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Candida infections 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Visceral leishmaniasis 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Coccidioidomycosis 5 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Histoplasmosis 5 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Zygomycosis 3 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Mucormycosis 3 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Sporotrichosis 3 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Aspergillus infections 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992

C_max

Value	Dose	Analyte	Population
7.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
57.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg 1 times / day multiple, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
31.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg 1 times / day multiple, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
83 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg 1 times / day multiple, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
83.7 μg/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg single, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
62.4 μg/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg 1 times / day multiple, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
27 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
65 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
269 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
60 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg 1 times / day multiple, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
197 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg 1 times / day multiple, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
555 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg 1 times / day multiple, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
476 μg × h/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg single, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
382 μg × h/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg 1 times / day multiple, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
10.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg 1 times / day multiple, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg 1 times / day multiple, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg 1 times / day multiple, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.5 h REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg single, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.9 h REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg 1 times / day multiple, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2.1% EXPERIMENT https://aac.asm.org/content/46/3/834.long			AMPHOTERICIN B plasma	Homo sapiens

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP3 246 OCT2 779 OAT1 725 BCRP 910 BSEP 550 P-gp 1741 MRP1 116 MRP2 499 MRP4 290 MRP5 31	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP1 232	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP2 625	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP3 326	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP4 345	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP5 80	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
OAT1 730	inhibitor 4027 Sources: https://aac.asm.org/content/58/10/5650.short Page: abstract	no
P-gp 1932	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
BCRP 985	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: abstract	weak [IC50 127 uM]
OCT2 782	inhibitor 4027 Sources: https://aac.asm.org/content/58/10/5650.short Page: abstract	yes [IC50 7.6 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://aac.asm.org/content/58/8/4464.short Page: abstract	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://icm-experimental.springeropen.com/articles/10.1186/2197-425X-3-S1-A213 Page: 1.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:2682	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2682
ChemicalBook	CB3425912	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3425912
eMolecules	30513061	https://www.emolecules.com/cgi-bin/more?vid=30513061
eMolecules	36772192	https://www.emolecules.com/cgi-bin/more?vid=36772192
MolPort	MolPort-006-113-274	https://www.molport.com/shop/molecule-link/MolPort-006-113-274
ZINC	ZINC000253387843	http://zinc15.docking.org/substances/ZINC000253387843

PubMed

Title	Date	PubMed
In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts.	2014	24366747
Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen.	2012-11	22869574
Injectable paromomycin for Visceral leishmaniasis in India.	2007-06-21	17582067
Discovery of novel indazole-linked triazoles as antifungal agents.	2007-06-15	17433670
Treatment of Bolivian mucosal leishmaniasis with miltefosine.	2007-02-01	17205440
Hypokalemic rhabdomyolysis in a child due to amphotericin B therapy.	2007-02	16906399
Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution.	2006-10-15	16983622
Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?	2006-09-30	17086508
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.	2006-08-15	16838223
Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.	2006-07	16269185
[Acute adverse effects following administration of liposomal amphotericin B].	2006-05	16762265
Amphotericin B-related nephrotoxicity in low-risk patients.	2006-04	16878259
Invasive fungal infection of the maxilla following dental extractions in a patient with chronic obstructive pulmonary disease.	2006-03	16545177
Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1.	2006-02-01	16189267
An unusual presentation of rhinofacial zygomycosis due to Cunninghamella sp. in an immunocompetent patient: a case report and literature review.	2006-01	16390472
Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients.	2006-01	16094544
Disseminated invasive aspergillosis in a patient with acute leukaemia.	2006	16918060
Amphotericin B-induced severe hypertension in a young patient: case report and review of the literature.	2006	16538979
Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review.	2005-11	16283214
[Amphotericin B associated with hypertension: haemodynamic profile].	2005-09-27	16183243
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening.	2005-09	16131481
Corticosteroid induced Cryptococcus meningitis.	2005-07	16100437
Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis.	2005-06	16117996
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.	2005-06	15868188
Study of renal safety in amphotericin B lipid complex-treated patients.	2005-05-01	15809928
Amphotericin B-induced nephrogenic diabetes insipidus in a case of cryptococcemia.	2005-05	15942094
Reversible dilated cardiomyopathy associated with amphotericin B treatment.	2005-05	15848302
Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.	2005-02	15702047
Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment.	2005-01	15610669
N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats.	2005	15637469
Fatal fat embolism following amphotericin B lipid complex injection.	2004-12	15507243
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.	2004-09-30	15459300
Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus.	2004-09	15497680
Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.	2004-09	15355408
Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants.	2004-06	15173544
Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.	2004-05	15059069
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS.	2004-03	14988693
Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.	2004-03	14730342
Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy.	2004-01	14661114
Reversible dilated cardiomyopathy related to amphotericin B therapy.	2004-01	14657095
Recent strategies for the chemotherapy of visceral leishmaniasis.	1999-12	17035822
Acute and chronic effects of flucytosine on amphotericin B nephrotoxicity in rats.	1992-12	1482135
Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function.	1992-11	1489202
Rapid intravenous infusion of amphotericin B: a pilot study.	1992-08	1497007
In-vivo and in-vitro studies on the effect of amphotericin B on endothelin release.	1992-01	1737726
Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients.	1992	1524911
Antifungal activity of HWA-138 and amphotericin B in experimental systemic candidiasis.	1991-10	1759826
The influence of Myrj 59 on the solubility, toxicity and activity of amphotericin B.	1991-05	1680169
LETHAL TOXICITY AND DOSE-RELATED AZOTEMIA DUE TO AMPHOTERICIN B IN DOGS.	1963-10	14076918

Patents

Sample Use Guides

In Vivo Use Guide

Mice were treated intraperitoneally once daily with 9 mg/kg of corifungin for 10 days. In rats, corifungin is safe up to a level of 250 mg/kg/day when administered by oral gavage for 28 days

Route of Administration: Other

In Vitro Use Guide

200 uM corifungin induces subcellular damage to A. castellanii (the presence of swollen mitochondria, electron-dense granules, degeneration of cytoplasm architecture, and loss of nuclear chromatin structure)

Substance Class	Chemical Created by `admin` on `Wed Apr 02 15:57:55 GMT 2025` Edited by `admin` on `Wed Apr 02 15:57:55 GMT 2025`
Record UNII	44WG8E9MTU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Amphotericin B deoxycholate [WHO-DD]

Preferred Name

English

Amphotericin B deoxycholate

Common Name

English

Code System Code Type Description

PUBCHEM

23668620